Developing novel treatments for central nervous system disorders such as Alzheimer's and Parkinson's.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Developing novel treatments for central nervous system disorders such as Alzheimer's and Parkinson's.
Released on: January 06, 2015. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Gunilla Osswald, CEO BioArtic Neuroscience
  • Summary
  • Transcript
  • Participants
  • Company
Gunilla Osswald, CEO BioArtic Neuroscience
Gunilla Osswald, CEO BioArtic Neuroscience
Gunilla Osswald
BioArtic Neuroscience
BioArtic Neuroscience

BioArctic Neuroscience AB was founded in 2003 by Prof. Lars Lannfelt and Dr. Pär Gellerfors, to explore important discoveries made by Prof. Lannfelt. These breakthrough discoveries, which have been internationally highly recognized, clarify the central role of protein misfolding in the neurodegenerative disease process. The company's proprietary technology has made it possible to develop new immunotherapeutic approaches to neurodegenerative diseases. BioArctic has a propriatery technology by which therapeutic monoclonal antibodies can be developed. These antibodies are highly specific for aggregated/misfolded proteins involved in disorders such as Alzheimer's and Parkinson's disease.